MarketInOut Stock Screener Log In | Sign Up
 

Guardant Health Inc

NASDAQ • Healthcare • Diagnostics & Research • Quote as of 10/23/2026
Guardant Health Inc stock price and volume chart

Company Profile

IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization21,866 mln
Float129 mln
Earnings Date11/05/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-2.91
Likely reliable

1-Year Forecast

201.64
Attractive

Relative Strength

74 / 100
Outperforming

Pre-Tax Margin

-38%
Deeply loss-making

ROE

211
Extraordinary

Business Description

Guardant Health is a cancer diagnostics company founded in 2011 and based in Palo Alto, California, that develops blood and tissue tests to detect and analyze cancer. Its products help doctors identify genetic changes in tumors, guiding treatment decisions for patients, and also include a blood test designed to screen healthy adults for colorectal cancer. The company additionally supports pharmaceutical research by offering data, software tools, and services that help connect patients with relevant clinical trials and advance the development of new cancer therapies.

Key Fundamentals

EPS-3.50
ROE211
RPS9.14
ROIC-67.98
ROA-26.83
Interest Cover-97.65
EBITDA, mln-411
EV / EBITDA-59.50
EV / EBIT-54.41
Revenue, mln1,183
EV / Revenue20.68

Quote Details

Last 169.08
Change 6.14 (3.77%)
Open 163.16
Volume 1,661,448
Turnover 280,917,632
Average Volume 1,752,690

Financial Ratios

Pre-Tax Profit Margin-38
Current Ratio4.03
Price / Sales19.51

Financial Strength

Altman Z-Score4.83
Piotroski F-Score 4 / 9
Beneish M-Score-2.91
1-Year Target Price201.64
Short Ratio6.50
Short % of Float9.25

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.61% 91 / 100   
1 Month -4.18% 43 / 100   
2 Months 14.19% 89 / 100   
6 Months 90.17% 98 / 100   
1 Year 149% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog